In last trading session, Fulcrum Therapeutics Inc (NASDAQ:FULC) saw 0.74 million shares changing hands with its beta currently measuring 2.06. Company’s recent per share price level of $4.37 trading at -$0.11 or -2.46% at ring of the bell on the day assigns it a market valuation of $235.72M. That closing price of FULC’s stock is at a discount of -213.5% from its 52-week high price of $13.70 and is indicating a premium of 34.55% from its 52-week low price of $2.86. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.7 million shares which gives us an average trading volume of 884.50K if we extend that period to 3-months.
For Fulcrum Therapeutics Inc (FULC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.57. Splitting up the data highlights that, out of 13 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information
Upright in the red during last session for losing -2.46%, in the last five days FULC remained trading in the red while hitting it’s week-highest on Monday, 01/06/25 when the stock touched $4.37 price level, adding 15.47% to its value on the day. Fulcrum Therapeutics Inc’s shares saw a change of -7.02% in year-to-date performance and have moved -9.71% in past 5-day. Fulcrum Therapeutics Inc (NASDAQ:FULC) showed a performance of 8.98% in past 30-days. Number of shares sold short was 4.97 million shares which calculate 7.67 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3.5 to the stock, which implies a fall of -24.86% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would jump 54.23% in reaching the projected high whereas dropping to the targeted low would mean a gain of 54.23% for stock’s current value.
Fulcrum Therapeutics Inc (FULC) estimates and forecasts
Statistics highlight that Fulcrum Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -43.97% of value to its shares in past 6 months, showing an annual growth rate of 89.94% while that of industry is 16.50. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.09% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 90.67% while estimates for its earnings growth in next 5 years are of 16.40%.
Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders
Insiders are in possession of 1.62% of company’s total shares while institution are holding 89.70 percent of that, with stock having share float percentage of 91.17%. Investors also watch the number of corporate investors in a company very closely, which is 89.70% institutions for Fulcrum Therapeutics Inc that are currently holding shares of the company. RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at FULC for having 11.61 million shares of worth $71.98 million. And as of 2024-06-30, it was holding 18.7302 of the company’s outstanding shares.
The second largest institutional holder is RTW INVESTMENTS, LP, which was holding about 5.85 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.4314 of outstanding shares, having a total worth of $36.24 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.85 shares of worth $8.09 million or 3.43% of the total outstanding shares. The later fund manager was in possession of 1.63 shares on Oct 31, 2024 , making its stake of worth around $7.11 million in the company or a holder of 3.01% of company’s stock.
